Switching antidepressants is one of the most common — and most botched — procedures in psychiatry. Done badly, the patient lands in discontinuation syndrome or a fortnight of untreated depression; done well, the transition is seamless. Knowing how to cross-taper between antidepressants safely comes down to three variables: the half-life of the drug you're stopping, how well the new agent covers the same receptors, and how much overlap the patient tolerates.

This is the practical playbook: the decision rules, an example-switch table, and the exact traps that show up in exams and in adverse-drug reactions.

Cross-taper versus direct switch versus washout

Three legitimate strategies exist:

  • Cross-taper — taper the old drug down while building the new one up, overlapping for one to several weeks. The default for most switches.
  • Direct switch — stop one day, start the next. Acceptable only between drugs with substantial receptor overlap (e.g., between SSRIs at equivalent doses) or in urgent situations.
  • Washout — stop, wait, then start. Required mainly around fluoxetine, whose norfluoxetine metabolite lingers 4–6 weeks, and around MAOIs.

The scaffold for every decision is the rule of three (the Maudsley prescribing convention): three half-lives for a new drug to reach steady state, three dose steps to cross-taper, three days between changes so you can attribute effects.

The half-life principle

Short half-life drugs (venlafaxine t½ ≈ 5 h, paroxetine ≈ 21 h, duloxetine ≈ 12 h) punish abrupt stops with paroxysmal withdrawal: electric-shock sensations, nausea, dizziness, irritability, insomnia. Long half-life drugs (fluoxetine t½ 1–3 days; norfluoxetine 4–16 days) self-taper — but they also linger, inflating interactions and washout windows.

Practical translation: the shorter the outgoing half-life, the gentler and longer the taper; the longer the outgoing half-life, the longer you wait before introducing something with serotonergic overlap (specifically the serotonin-syndrome window — see our psychopharmacology notes).

Example switches

SwitchStrategyRough timing
Paroxetine → venlafaxineCross-taper over 1–2 weeksParoxetine −10 mg steps, venlafaxine +37.5/75 mg steps
Fluoxetine → any SSRI/SNRIStop fluoxetine, washout 4–6 weeks, then startLongest gap of any common switch
SSRI → mirtazapineDirect or short overlapMirtazapine's noradrenergic profile gives little serotonergic conflict
Venlafaxine → escitalopramSlow cross-taper (2–4 weeks)Watch for discontinuation shocks; dose venlafaxine down in 75 mg steps
Any SSRI → MAOIFull washout (2–4 weeks; 1–2 weeks for fluoxetine→MAOI per NICE)Serotonin-syndrome risk if shortened
Clomipramine → SSRIVery cautious overlap or washoutAdditive serotonergic + cardiac conduction risk

Always confirm exact washout intervals against the current NICE NG222 guidance or the SmPC — they vary by drug pair and renal/hepatic function.

Step-by-step: running the switch

  1. Confirm the reason — non-response (dose/optimal trial first), intolerance, or drug-drug interaction. Switching within class for "partial response" before a full dose trial is the commonest error.
  2. Choose the target — pick the new drug's starting dose conservatively; depressed patients often tolerate only half the usual starting dose during a switch.
  3. Taper the outgoing drug over 1–2 weeks in 2–3 steps (the rule of three), holding ≥3 days between steps.
  4. Build the incoming drug in stepwise increments, watching for activation, GI upset, and serotonin toxicity in the overlap window.
  5. Review at 2 weeks — discontinuation symptoms should be settling; if mood is deteriorating, reassess rather than assuming "they need a higher dose of everything".

Recognising discontinuation syndrome

Withdrawal symptoms begin within 1–3 days of a missed dose or rapid taper and mirror neither the original depression nor anxiety precisely: "brain zaps," nausea, vertigo, flu-like malaise, vivid dreams, irritability. Key discriminators from relapse — timing within days of the change, physical quality, and rapid improvement when the old drug is reinstated.

Exam trap

Two classics. First: a patient on fluoxetine for years switched directly to sertraline "because they're both SSRIs" — the correct answer flags the 4–6 week norfluoxetine washout. Second: symptoms of dizziness, "electric shocks" and nausea three days after stopping paroxetine are discontinuation syndrome, not relapse; the fix is reinstatement and a slower taper, not dose escalation. If an option says "stop the antidepressant abruptly", it is wrong unless a specific toxicity demands immediate cessation.

Special situations and edge cases

Pregnancy and breastfeeding. Paroxetine's historical cardiac-signal baggage makes newer SSRIs (sertraline, citalopram/escitalopram) the usual choices, and switches should be planned with obstetric input — abrupt changes in either direction carry more risk than a slow, documented cross-taper.

Elderly patients and polypharmacy. Reduce the target dose: start at half the usual adult dose and titrate slower. Every new agent added in this population should be checked against the full medication list for CYP-level interactions, not just serotonergic overlap.

Partial responders versus intolerances. The taper logic differs. For intolerance (activation, sexual dysfunction, weight gain), move faster — the outgoing drug is causing harm now. For partial response, allow a fuller trial at dose optimisation first; switching earlier is one of the most common causes of apparent "treatment resistance."

Benzodiazepine overlap. If a patient arrives on a benzodiazepine alongside the antidepressant being switched, taper the benzodiazepine as a separate, later project — changing two variables at once destroys your ability to attribute adverse effects (the rule of three protects here too).

Documentation. Record the exact planned schedule: outgoing drug, steps and dates; incoming drug, steps and dates; what symptom change would prompt review. A written plan shared with the patient prevents the most common real-world failure mode — the patient improvising their own schedule at week two.

Finally, a note on expectations: switches are experiments, not guarantees. Tell the patient what improvement should look like and by when — sleep and appetite often move first, mood lags by two to four weeks — so an early plateau prompts a scheduled review rather than premature despair or another switch.

Frequently asked questions

How long should a cross-taper between antidepressants take?

Typically 1–2 weeks for most SSRI-to-SSRI or SSRI-to-SNRI switches, extending to 2–4 weeks for drugs prone to discontinuation symptoms such as paroxetine and venlafaxine. The Maudsley rule of three suggests three taper steps with at least three days between each.

Why do you have to wait after stopping fluoxetine?

Fluoxetine's active metabolite norfluoxetine has a half-life of 4–16 days, so it persists for 4–6 weeks after the last dose. Starting another serotonergic agent during that window compounds serotonin-syndrome risk and confounds side-effect attribution.

Can you cross-taper two SSRIs at the same time?

Overlapping two SSRIs is generally avoided because of additive side effects and serotonin toxicity risk; the standard approaches are a short taper with a brief gap or a planned cross-taper with the outgoing drug reduced in defined steps. Any deliberate overlap should be brief, low-dose and documented.

How do you tell discontinuation syndrome from relapse?

Discontinuation starts within 1–3 days of the dose change, has physical symptoms (electric-shock sensations, nausea, vertigo, flu-like feelings) and improves on reinstatement. Relapse develops over weeks, brings back the original mood symptoms, and does not improve when the previous drug is restarted.

Key takeaways

  • Three strategies: cross-taper (default), direct switch (close relatives only), washout (fluoxetine, MAOIs).
  • Half-life drives everything: shorter outgoing half-life = gentler taper; longer = longer washout.
  • Rule of three: three dose steps, three days apart, three half-lives to steady state.
  • Discontinuation syndrome begins within days and is physical — relapse takes weeks and is emotional.
  • Fluoxetine's 4–6 week washout and abrupt-stop questions are recurring exam content.

Practise switch scenarios in Preppsy's MCQ mock exams, or review drug half-lives in the concept library before your next pharmacology block.

Cover image: “Cross-Tapering Antidepressants (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.